saint Julien en Genevois, France

Alicia Contet

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Pierre Fabre Medicament. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alicia Contet: Innovator in Cancer Treatment

Introduction

Alicia Contet is a prominent inventor based in Saint Julien en Genevois, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of immunocytokines. Her work focuses on creating new therapeutic options for patients battling cancer.

Latest Patents

Alicia Contet holds a patent for her invention titled "Immunocytokines for the treatment of cancer." This patent describes novel immunocytokines that are designed to be effective in treating cancer. The fusion proteins involved in this invention consist of an antibody or an antigen-binding fragment fused to a cleavable peptide linker, along with a cytokine or its functional fragments. The methods of treatment utilizing these immunocytokines are also detailed in her patent. She has 1 patent to her name.

Career Highlights

Alicia Contet is currently associated with Pierre Fabre Medicament, where she continues her research and development efforts. Her work at this esteemed company has allowed her to focus on innovative solutions in the medical field, particularly in oncology.

Collaborations

Alicia has collaborated with notable colleagues, including Céline Bertaux and Martine Malissard. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Alicia Contet is a dedicated inventor whose work in immunocytokines represents a significant advancement in cancer treatment. Her contributions are paving the way for new therapeutic strategies that could benefit many patients in the future.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…